Crédit Agricole S.A. : The target price as per the weekly chart was reached
Entry price | Target | Stop-loss | Potential |
---|
€11.82 |
€11 |
€12.2 |
+6.94% |
---|
Below the resistance levels that are currently being tested and which are situated around 11.9 EUR, the beginning of a correction phase for shares in Crédit Agricole appears to be the most likely scenario.
Strengths● The group's activity appears highly profitable thanks to its outperforming net margins.
● Its low valuation, with P/E ratio at 9.64 and 11.43 for the ongoing fiscal year and 2017 respectively, makes the stock pretty attractive with regard to earnings multiples.
● The company is one of the best yield companies with high dividend expectations.
● For the last few months, EPS revisions have remained quite promising. Analysts now anticipate higher profitability levels than before.
● The stock is in a well-established, long-term rising trend above the technical support level at 9.52 EUR
Weaknesses● Stock prices approach a strong long-term resistance in weekly data at EUR 11.9.
● The stock is close to a major daily resistance at EUR 11.98, which should be gotten rid of so as to gain new appreciation potential.
● According to forecast, a sluggish sales growth is expected for the next fiscal years.
The content herein constitutes a general investment recommendation, prepared in accordance with provisions aimed at preventing market abuse by Surperformance, the publisher of MarketScreener.com. More specifically, this recommendation is based on factual elements and expresses a sincere, complete, and balanced opinion. It relies on internal or external data, considered reliable as of the date of their release. Nevertheless, this information, and the resulting recommendation, may contain inaccuracies, errors, or omissions, for which Surperformance cannot be held responsible. This recommendation, which in no way constitutes investment advice, may not be suitable for all investor profiles. The reader acknowledges and accepts that any investment in a financial instrument involves risks, for which they assume full responsibility, without recourse against Surperformance. Surperformance commits to disclosing any conflict of interest that may affect the objectivity of its recommendations.